Gross Profit Trends Compared: Novartis AG vs Amgen Inc.

Gross Profit Trends: Novartis AG vs Amgen Inc.

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of two giants: Novartis AG and Amgen Inc., from 2014 to 2023. Over this period, Novartis AG consistently outperformed Amgen Inc. in terms of gross profit, with an average of approximately 35 billion USD annually, compared to Amgen's 19 billion USD. However, Amgen showed a remarkable growth rate, increasing its gross profit by about 26% from 2014 to 2023, while Novartis experienced a more modest growth of around 6%. Notably, 2021 marked a peak for Novartis, reaching a gross profit of 37 billion USD, while Amgen's highest was in 2022 at nearly 20 billion USD. These trends highlight the dynamic nature of the pharmaceutical sector and the strategic maneuvers companies must employ to maintain competitive advantage.